The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab

作     者：Sabine Lieb Sebastian Ebel Daniel Seehofer Thomas Berg Florian van Bommel 

作者机构：Division of HepatologyDepartment of Medicine IILeipzig University Medical CenterLeipzigGermany Department of Diagnostic and Interventional RadiologyLeipzig University Medical CenterLeipzigGermany Department of VisceralVascularThoracic and Transplant SurgeryLeipzig University Medical CenterLeipzigGermany 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2023年第12卷第1期

页      面：148-150页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：patients hepatocellular carcinoma 

摘      要：With great interest we have read the comment of *** on the recently published CRAFITY score for the prediction of response to anti-programmed death(ligand)1[PD-(L)1]-based immunotherapy in patients with unresectable hepatocellular carcinoma(HCC)(1).